Amryt Pharma PLC

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded in August 2015 and is headquartered in Dublin, Ireland.

Amryt Supports FH Awareness Day – September 24, 202 2

Amryt Supports FH Awareness Day – September 24, 2022

CHMP a dopts p ositive o pinion for Mycapssa ® for the t reatment of Acromegaly

CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly

Amryt R eceives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022

The mean of analysts' price targets for Amryt Pharma PLC Sponsored ADR (AMYT) points to an 187.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?

Amryt Pharma plc (NASDAQ:AMYT ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - Chief Executive Officer Rory Nealon - Chief Financial Officer and Chief Operating Officer Jordi Casals - President of EMEA Region Sheila Frame - President of Americas Tracy Cunningham - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright & Co. Max Herrmann - Stifel, Nicolaus & Company, Inc. Brian White - Shore Capital Stockbrokers Ltd.

Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates

DUBLIN, Ireland, and Boston MA, July 21 , 202 2 , Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2022 will be released on Thursday , August 4 , 202 2 at 0700 E T/1200 BST.

Amryt to Report Q2 2022 Results on August 4, 2022

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the T reatment of C arcinoid S y ndrome

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt Presents New Analys e s from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

European Commission Approves Filsuvez® for the t reatment of Dystrophic and Junctional EB

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

P osting of A nnual Report and Notice of AGM

Posting of Annual Report and Notice of AGM

Amryt Announces Details of EMA Contingent Value Rights Payment

Amryt Pharma PLC (NASDAQ:AMYT ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - CEO & Director Rory Nealon - CFO, COO & Company Secretary Sheila Frame - President of Americas Tracy Cunningham - VP, Head of Development Paul Greenland - President, EMEA Region Conference Call Participants Max Herrmann - Stifel, Nicolaus & Company Mani Foroohar - SVB Leerink Catherine Novack - Jones Research Michelle Gilson - Canaccord Genuity Brandon Folkes - Cantor Fitzgerald & Co. Operator Good day, and thank you for standing by. Welcome to the Amryt Pharma Q1 Results Call.

Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 0% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates

Amryt Reports Record Q1 2022 Results

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed the approval of Amryt Pharma Plc's (NASDAQ: AMYT) Filsuvez in the European Union for partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa.

Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease

CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB

A mryt to Report Q1 202 2 Results on May 4 , 2022

News for Amryt Pharma PLC Stock (AMYT)